Know Cancer

forgot password

Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer

Phase 2
18 Years
Not Enrolling
Lung Cancer

Thank you

Trial Information

Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer

Inclusion Criteria:

- Patients must have pathologically confirmed SCLC at MSKCC that has progressed after
one or two chemotherapy regimens.

- At least 3 weeks must have elapsed since last chemotherapy or radiation treatment and
initiation of study treatment.

- Karnofsky performance status > or = to 60%.

- Patients must have measurable disease, this can include brain metastases.

- Patients must have normal organ and marrow function as defined below:

- − leukocytes > 3,000/mcL

- platelets > 100,000/mcL

- total bilirubin < 1.5 mg/dL

- AST(SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal

- Creatinine < 2.0 mg/dl

- For women of child-bearing potential, negative pregnancy test within 7 days prior to
starting temozolomide.

- Men and women of childbearing potential must agree to practice adequate

- Ability to understand and the willingness to sign a written informed consent

- Both men and women of all races and ethnic groups are eligible for this trial.

Exclusion Criteria:

- Patients who have not recovered from adverse events of previous therapies.

- Patients receiving other investigational agents.

- Patients with leptomeningeal involvement.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, or
psychiatric illness/social situations that would limit compliance with study

- Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition or
HIV-positive patients on combination antiretroviral therapy. However, HIV testing is
not required for entry into this protocol. The need to exclude patients with AIDS
from this protocol is necessary because these patients are at increased risk of
lethal infections when treated with marrow- suppressive therapy. Excluding patients
on HAART is necessary due to the potential for pharmacokinetic interactions with

- Women who are pregnant or breast feeding, due to possible adverse effects on the
developing fetus or infant due to study drug.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The objective overall response rate, which will be stratified for sensitive and refractory disease.

Outcome Time Frame:

conclusion of study

Safety Issue:


Principal Investigator

Maria Pietanza, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

August 2008

Completion Date:

February 2013

Related Keywords:

  • Lung Cancer
  • Lung
  • Lung Neoplasms
  • Small Cell Lung Carcinoma



Memorial Sloan-Kettering Cancer Center New York, New York  10021
Memorial Sloan-Kettering Cancer Center at Commack Commack, New York  11725
Memorial Sloan-Kettering Cancer Center at Mercy Medical Center Rockville Centre, New York  11570
Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey  
Memoral Sloan Kettering Cancer Center@Phelps Sleepy Hollow, New York